Clinical and Translational Oncology

, Volume 8, Issue 8, pp 560–565

Therapeutic opportunities and targets in childhood leukemia

  • Anthony M. Ford
  • Ángel Martínez-Ramírez
Educational Series Green Series

DOI: 10.1007/s12094-006-0061-5

Cite this article as:
Ford, A.M. & Martínez-Ramírez, Á. Clin Transl Oncol (2006) 8: 560. doi:10.1007/s12094-006-0061-5


Childhood leukemia is a common pediatric cancer in the developed world, the disease is biologically diverse and there is much discussion as to its causal mechanisms. Acute lymphoblastic leukemia (ALL) is the most common subtype and infants with ALL have a greatly increased risk of treatment failure. There are molecular and biological properties of leukemic cells that determine treatment outcome; these can usually be attributed to distinct genetic abnormalities that alter the normal proliferative and survival signals of hematopoietic cells. Experimental evidence for the existence of leukemic stem cells (LSC) has been obtained, and it is presumed that these cells arise from mutations in normal hematopoetic stem cells or progenitor cells, and they are difficult to eradicate. LSC seem to be surprisingly different from their normal counterparts and therefore are obvious new targets for drug therapy. Therapeutic concepts using monoclonal antibodies have substantially improved response rates in patients with malignant lymphomas and are currently being evaluated in other types of cancer.

Key words

acute lymphoblastic leukemiachromosome translocationsfusion genesleukemic stem cellimmunotherapymonoclonal antibodies

Copyright information

© FESEO 2006

Authors and Affiliations

  • Anthony M. Ford
    • 1
  • Ángel Martínez-Ramírez
    • 2
  1. 1.Section of Haemato-OncologyInstitute of Cancer ResearchSuttonUK
  2. 2.Molecular Cytogenetics LaboratoryMD Anderson International EspañaMadridSpain